Idexx Laboratories price target lowered to $800 from $830 at BTIG

BTIG lowered the firm’s price target on Idexx Laboratories (IDXX) to $800 from $830 and keeps a Buy rating on the shares. The company delivered a good Q4 beat on the top and bottom line and initiated 2026 guidance bracketing the Street estimates, though the 5% pullback in the stock was a function of the Street wanting to see a stronger outlook, including on pet visits, which the company expects to remain about a 200bps drag in 2026, the analyst tells investors in a research note.